NCT06123494View on ClinicalTrials.gov

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

PHASE3RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

January 9, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

SHR-A1811

SHR-A1811 6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle

DRUG

Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan

Ramucirumab 8mg/kg，D 1,15 + Paclitaxel 80mg/m2，D1,8,15，Q4W; Paclitaxel 80mg/m2，D1,8,15，Q4W; Docetaxel 75mg/m2，D1，Q3W; Irinotecan 150mg/m2，D1，Q2W.

Trial Locations (1)

200433

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY